Prognostic value of combined MTV and ADC derived from baseline FDG PET/MRI in aggressive non-Hodgkins lymphoma

BMC Cancer

Table 1 Study patient population. Baseline characteristics, treatment, and treatment response

Patient population	N = 33
Age, median	63
Age > 60	22
Gender
Male	22
Female	11
Histology
DLBCL	30
HGBCL	3
Number of extranodal sites
≥ 2	10
Ann Arbor stage
I-II	10
III-IV	23
Bulky tumor ≥10 cm	18
Prognostic score, IPI
IPS 0–3	26
High: IPS ≥ 4–5	7
Elevated LDH	15
B-symptoms	12
ECOG PS
≥ 2	6
Systemic treatment
R-CHOP/R-CHOEP	30
DA-EPOCH-R	2
GMALL-2002 + auto SCT	1
Consolidating radiation therapy	12
Response to treatment
CMR	27
PD	4
Death during treatment	2

DLBCL Diffuse Large B-cell lymphoma, HGBCL High-grade B-cell lymphoma, IPI International Prognostic Index, LDH Lactate Dehydrogenase, ECOG PS Eastern Cooperative Oncology Group Performance Status, R-CHOP/R-CHOEP Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone/Etoposide, DA-EPOCH-R Dose-adjusted Etoposide, Prednisolone, Vincristine, Cyclophosphamide, Doxorubicin and Rituximab GMALL-2002 = Blocks of cycles A,B and C containing Rituximab and intensive chemotherapy, auto SCT Autologous stem cell transplant, CMR complete metabolic response, PD progressive disease

ISSN: 1471-2407